Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Pharmaceuticals, a subsidiary of Mylan, has obtained the US Food and Drug Administration's (FDA) final approval for its abbreviated new drug application (ANDA) for Latanoprost Ophthalmic Solution, 0.005%.
Subscribe to our email newsletter
Latanoprost Ophthalmic Solution, 0.005% is the generic version of Pharmacia and Upjohn’s Xalatan Ophthalmic Solution, an eyedrop that lowers pressure in the eye.
Latanoprost reduces pressure in the eye by increasing the amount of fluid that drains from the eye.
Latanoprost ophthalmic (for the eyes) is used to treat certain types of glaucoma and other causes of high pressure inside the eye.
Mylan president Heather Bresch said they are very pleased to introduce this product to the market as it represents Mylan’s first ophthalmic solution.